Last reviewed 2026-04-20 · How we verify

Enlon-Plus (Atropine Sulfate)

Atropine antagonizes muscarine-like actions of acetylcholine through competitive antagonism at peripheral muscarinic receptors.

Atropine Sulfate Injection is an antimuscarinic agent indicated for temporary blockade of severe or life-threatening muscarinic effects including organophosphorus poisoning and bradyasystolic cardiac arrest. It competitively antagonizes muscarinic acetylcholine receptors on peripheral structures with no absolute contraindications. The drug may cause transient cardiac stimulation before tachycardia develops and can interact with mexiletine by delaying absorption. Atropine remains a critical emergency antidote with established clinical utility in acute poisoning and cardiac dysrhythmia management.

At a glance

Mechanism of action

Atropine is an antimuscarinic agent that antagonizes the muscarine-like actions of acetylcholine and other choline esters. It inhibits muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to endogenous acetylcholine. The antagonism is competitive or surmountable, meaning it can be overcome by increasing acetylcholine concentration at receptor sites, such as through anticholinesterase agents that inhibit acetylcholine enzymatic destruction. Atropine antagonizes receptors on peripheral structures stimulated or inhibited by muscarine, including exocrine glands and smooth and cardiac muscle. Responses to postganglionic cholinergic nerve stimulation may also be inhibited, though less readily than responses to injected exogenous choline esters. Atropine-induced parasympathetic inhibition may be preceded by transient stimulation, particularly on the heart where small doses initially slow the rate before characteristic tachycardia develops due to vagal paralysis. Atropine exerts more potent and prolonged effects on heart, intestine, and bronchial muscle than scopolamine, though its action on iris, ciliary body, and certain secretory glands is weaker than scopolamine.

Approved indications

• Perioperative Mydriasis

Common side effects

• irritation in the area of instillation
• Burning sensation
• Blurred vision
• Headache
• Pruritus
• Ocular hyperemia
• Anemia
• Diarrhea
• Fever
• Hypertension
• Nausea
• Platelet count decreased

Drug interactions

• Mexiletine

Key clinical trials

• E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
• PRO-201 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.